Regulation of the neutralizing anti-hepatitis B surface (HBs) antibody response in vitro in HBs vaccine recipients and patients with acute or chronic hepatitis B virus (HBV) infection
- PMID: 8697635
- PMCID: PMC2200470
- DOI: 10.1046/j.1365-2249.1996.d01-732.x
Regulation of the neutralizing anti-hepatitis B surface (HBs) antibody response in vitro in HBs vaccine recipients and patients with acute or chronic hepatitis B virus (HBV) infection
Abstract
Antibodies directed to the HBs antigen indicate viral clearance and the development of life-long immunity in patients that recovered from HBV infection. In HBs antigen vaccine recipients anti-HBs antibodies provide protective immunity. However, little is known about the regulation of this HBs-specific antibody response. The existence of anti-HBs-secreting B cells was demonstrated using the highly sensitive ELISPOT technique compared with conventional ELISA in serum and cell culture supernatants. In the peripheral blood of patients with acute self-limited hepatitis B, HBs-specific B cells were demonstrated with a high frequency despite undetectable anti-HBs serum antibodies. HBV-immunized patients that had recovered from infection and vaccine recipients had significantly lower frequencies, whereas chronic HBV carriers and negative controls showed no anti-HBs-secreting B cells. Coculture experiments of isolated B and T cells revealed that the anti-HBs antibody response was restricted to the presence of T helper cells, but not to identical HLA class II molecules. Allogeneic T cells derived from vaccine recipients or chronic HBV carriers stimulated the HBs-specific B cell response in HBs vaccine recipients. Otherwise, isolated T helper cells could never provide sufficient help to induce the HBs-specific B cell responses in chronic HBV carriers. Furthermore, peripheral blood mononuclear cells (PBMC) of six out of 10 vaccine recipients, one out of five HBV-immunized patients, but of no chronic HBV carrier showed a proliferative response to different HBs antigen preparations. This study demonstrated a high frequency of circulating anti-HBs-producing B cells in the early phase of acute HBV infection, but a lower frequency of HBs-specific B cells years after resolution of HBV infection. In chronic HBV carriers. However, deficient HBs-specific T and B cell responses were observed.
Similar articles
-
Kinetics of hepatitis B surface antigen-specific immune responses in acute and chronic hepatitis B or after HBs vaccination: stimulation of the in vitro antibody response by interferon gamma.Hepatology. 1999 Jan;29(1):238-44. doi: 10.1002/hep.510290120. Hepatology. 1999. PMID: 9862872 Clinical Trial.
-
Immunoregulation of the in vitro anti-HBs antibody synthesis in chronic HBsAg carriers and in recently boosted anti-hepatitis B vaccine recipients.Clin Exp Immunol. 1985 May;60(2):259-66. Clin Exp Immunol. 1985. PMID: 3874020 Free PMC article.
-
A Longitudinal Hepatitis B Vaccine Cohort Demonstrates Long-lasting Hepatitis B Virus (HBV) Cellular Immunity Despite Loss of Antibody Against HBV Surface Antigen.J Infect Dis. 2016 Jul 15;214(2):273-80. doi: 10.1093/infdis/jiw142. Epub 2016 Apr 7. J Infect Dis. 2016. PMID: 27056956 Free PMC article.
-
Expression and detection of anti-HBs antibodies after hepatitis B virus infection or vaccination in the context of protective immunity.Arch Virol. 2019 Nov;164(11):2645-2658. doi: 10.1007/s00705-019-04369-9. Epub 2019 Aug 9. Arch Virol. 2019. PMID: 31399876 Review.
-
The significance of antibody to hepatitis B surface antigen in infection and clearance of hepatitis B virus.Hum Vaccin Immunother. 2025 Dec;21(1):2445283. doi: 10.1080/21645515.2024.2445283. Epub 2025 Jan 3. Hum Vaccin Immunother. 2025. PMID: 39754388 Review.
Cited by
-
KASL clinical practice guidelines: management of chronic hepatitis B.Clin Mol Hepatol. 2016 Mar;22(1):18-75. doi: 10.3350/cmh.2016.22.1.18. Epub 2016 Mar 28. Clin Mol Hepatol. 2016. PMID: 27044762 Free PMC article. Review. No abstract available.
-
Skewed CD39/CD73/adenosine pathway contributes to B-cell hyperactivation and disease progression in patients with chronic hepatitis B.Gastroenterol Rep (Oxf). 2020 Aug 30;9(1):49-58. doi: 10.1093/gastro/goaa048. eCollection 2021 Jan. Gastroenterol Rep (Oxf). 2020. PMID: 33747526 Free PMC article.
-
Antigen-specific B and T cells in human/mouse radiation chimera following immunization in vivo.Immunology. 1999 Apr;96(4):634-41. doi: 10.1046/j.1365-2567.1999.00704.x. Immunology. 1999. PMID: 10233752 Free PMC article.
-
The study of efficacy of lamivudine in patients with severe acute hepatitis B.Dig Dis Sci. 2010 Mar;55(3):775-83. doi: 10.1007/s10620-009-1060-5. Epub 2009 Dec 3. Dig Dis Sci. 2010. PMID: 19957031 Clinical Trial.
-
Reversal of B-cell hyperactivation and functional impairment is associated with HBsAg seroconversion in chronic hepatitis B patients.Cell Mol Immunol. 2015 May;12(3):309-16. doi: 10.1038/cmi.2015.25. Epub 2015 Apr 6. Cell Mol Immunol. 2015. PMID: 25849120 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials